
|Articles|October 1, 2002
VitrenASE: Immusol starts trial for potential PVR drug
San Diego-Immusol has begun a phase II clinical trial for its VitrenASE, a potential treatment for proliferative vitreoretinopathy (PVR) that could reduce the incidence of repeat retinal detachment after surgical repair.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
2
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
3
Collarettes common but largely stable in moderate-to-severe dry eye patients
4
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada
5

















































.png)


